Translational findings support regimen selection for first‐in‐human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer

Documenti analoghi

• First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome
  di: Rupa Narayan, et al.
  Pubblicazione: (2024)
• Siglec15/ TGF ‐β bispecific antibody mediates synergistic anti‐tumor response against 4T1 triple negative breast cancer in mice
  di: Limei Shen, et al.
  Pubblicazione: (2024)
• Feasibility and pharmacokinetic evaluation of a needle‐free injector for delivering high concentration antibody formulations
  di: Alexander Josowitz, et al.
  Pubblicazione: (2025)
• The CD147 expression in CD4+ T cells is a novel biomarker for predicting efficacy of IL‐17A inhibitor and psoriasis recurrence
  di: Panpan Liu, et al.
  Pubblicazione: (2024)
• Bispecific antibody targeting CD40 and HER2 potentiates therapeutic efficacy by reprogramming macrophages within the tumour microenvironment
  di: Na Li, et al.
  Pubblicazione: (2025)